- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
- Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Aileron Therapeutics Announces CEO Transition
- Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
More ▼
Key statistics
On Thursday, Aileron Therapeutics Inc (ALRN:NAQ) closed at 3.82, 278.22% above the 52 week low of 1.01 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.29 |
---|---|
High | 4.30 |
Low | 3.76 |
Bid | 3.50 |
Offer | 4.09 |
Previous close | 4.16 |
Average volume | 164.36k |
---|---|
Shares outstanding | 16.97m |
Free float | 16.11m |
P/E (TTM) | -- |
Market cap | 70.61m USD |
EPS (TTM) | -3.39 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼